Last updated: February 8, 2026
Who Are the Main Suppliers of Etripamil?
Etripamil is an investigational calcium channel blocker developed for acute episodic migraine and potentially other cardiovascular applications. It is not yet commercially available, which limits the number of active suppliers and manufacturers but points to key players involved in its development and early commercialization stages.
What Are the Leading Companies Involved in Etripamil Development?
Neurelis, Inc.
- Development Stage: Leading developer and patent holder; actively advancing Etripamil through clinical trials.
- Partnerships: Collaborates with contract manufacturing organizations (CMOs) for production scale-up.
- Focus: Proprietary nasal spray formulation intended for rapid absorption and onset.
Other Biopharmaceutical Companies
- Potential Manufacturers: Contract manufacturing organizations (CMOs) such as Catalent, Patheon (Thermo Fisher), and Piramal are capable of producing nasal spray formulations at scale.
- Small biotech and research organizations may engage in early-stage synthesis or supply of raw materials, but they are not publicly identified as Etripamil-specific suppliers.
What Are the Supply Chain Components?
Raw Material Suppliers
- Calcium Channel Blocker Precursors: Suppliers of high-purity chemicals used in synthesis, such as calcium chloride, which are generally supplied by companies like Merck or Sigma-Aldrich.
- Formulation Ingredients: Excipients for nasal spray delivery, including preservatives and stabilizers, are sourced from pharmaceutical-grade ingredient suppliers such as Roquette or BASF.
Manufacturing and Packaging
- Contract Manufacturers: Facilities with Good Manufacturing Practice (GMP) certification capable of formulating nasal spray medications.
- Packaging Suppliers: Companies like Gerresheimer and West Pharmaceutical Services provide specialized containers and nasal delivery devices.
What Are the Key Considerations for Etripamil Suppliers?
- Regulatory Compliance: Suppliers must comply with FDA or EMA regulations for pharmaceutical ingredients.
- Quality Assurance: Validation of raw materials and finished products for purity, stability, and bioavailability.
- Manufacturing Capacity: Ability to meet clinical trial and eventual commercial demand should Etripamil progress through approval.
How Does the Supply Chain Compare With Similar Drugs?
| Aspect |
Etripamil |
Typical Nasal Spray Drugs |
Injectable Calcium Channel Blockers |
| Development Stage |
Clinical (Phase II/III) |
Approved and commercialized |
Range from approved to investigational |
| Main Suppliers |
Neurelis, CMOs |
Ingredient suppliers, CMOs |
Raw material suppliers, CMOs |
| Number of Active Suppliers |
Limited, focused on Neurelis |
Multiple across regions |
Few, focusing on large pharma |
Future Outlook for Etripamil Suppliers
As Etripamil advances through regulatory review, the supplier network will expand to ensure manufacturing capacity for commercial distribution. Supply agreements are expected to focus on high-purity raw materials, formulation expertise, and scalable manufacturing.
Key Takeaways
- Etripamil's development involves a small, focused supplier network primarily led by Neurelis.
- Core raw material suppliers include chemical providers for calcium channel blocker synthesis and excipient vendors for nasal formulation.
- Contract manufacturing organizations are critical for scalable production, with GMP compliance being essential.
- The supply chain is characterized by a limited number of specialized vendors, with potential growth upon regulatory approval.
- Supply considerations differ significantly from established drugs, given Etripamil's investigational status.
FAQs
1. Who are the primary manufacturers involved in producing Etripamil?
Neurelis manages clinical manufacture, partnering with CMOs for scale-up, but specific suppliers are not publicly disclosed.
2. Are there any designated raw material suppliers for Etripamil?
No specific raw material suppliers are publicly identified; general chemical providers supply calcium channel blocker precursors.
3. When is Etripamil expected to reach the market?
As of the latest updates, Etripamil remains in late-stage clinical trials; regulatory approval timelines are pending.
4. Can existing nasal spray manufacturing companies produce Etripamil?
Yes, firms with GMP-compliant nasal spray manufacturing lines could produce Etripamil once specifications are finalized.
5. Is there competition among suppliers for Etripamil?
Given its investigational status, competition is minimal; supplier relationships are likely exclusive or limited to specific contracts.
Citations
- Neurelis Inc. Clinical Trial Registry. [URL]
- Sigma-Aldrich Raw Materials Catalog. [URL]
- BASF Product Portfolio. [URL]
- GMP Manufacturing Guidelines. U.S. FDA. [URL]
- Market Analysis of Nasal Spray Drugs. IQVIA. [URL]
